Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
SIX:BSLN
Price:
58.2
CHF
Market Closed
Market Cap:
CHf705.5m
Balance Sheet
Balance Sheet Decomposition
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG
Balance Sheet Decomposition is not available for
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG
Balance Sheet
Basilea Pharmaceutica AG
Basilea Pharmaceutica AG
Currency: CHF
| Dec-2002 | Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
133
|
172
|
224
|
61
|
27
|
27
|
239
|
201
|
173
|
109
|
61
|
54
|
85
|
60
|
121
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
118
|
111
|
204
|
61
|
27
|
27
|
33
|
50
|
37
|
53
|
50
|
54
|
35
|
8
|
14
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
61
|
20
|
0
|
0
|
0
|
206
|
151
|
136
|
57
|
11
|
0
|
50
|
52
|
107
|
|
| Short-Term Investments |
112
|
76
|
203
|
230
|
177
|
425
|
294
|
178
|
150
|
25
|
120
|
213
|
199
|
337
|
0
|
60
|
50
|
20
|
101
|
95
|
0
|
0
|
0
|
|
| Total Receivables |
7
|
1
|
1
|
1
|
1
|
3
|
8
|
5
|
11
|
13
|
12
|
7
|
8
|
5
|
7
|
15
|
36
|
30
|
32
|
64
|
62
|
58
|
58
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
8
|
11
|
8
|
4
|
1
|
2
|
2
|
5
|
4
|
6
|
9
|
0
|
33
|
28
|
9
|
|
| Other Receivables |
6
|
1
|
1
|
1
|
1
|
3
|
6
|
3
|
3
|
2
|
4
|
3
|
7
|
3
|
5
|
10
|
32
|
24
|
24
|
0
|
29
|
30
|
49
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
4
|
0
|
0
|
5
|
10
|
15
|
15
|
14
|
19
|
21
|
23
|
24
|
26
|
32
|
|
| Other Current Assets |
1
|
1
|
2
|
2
|
5
|
6
|
3
|
2
|
2
|
6
|
5
|
5
|
5
|
6
|
7
|
2
|
2
|
7
|
8
|
5
|
5
|
8
|
10
|
|
| Total Current Assets |
120
|
77
|
206
|
232
|
182
|
434
|
305
|
186
|
300
|
219
|
360
|
286
|
245
|
385
|
268
|
293
|
275
|
185
|
224
|
241
|
175
|
152
|
221
|
|
| PP&E Net |
27
|
26
|
22
|
20
|
18
|
19
|
20
|
18
|
16
|
16
|
14
|
13
|
12
|
11
|
9
|
8
|
6
|
5
|
5
|
3
|
22
|
21
|
19
|
|
| PP&E Gross |
27
|
26
|
22
|
20
|
18
|
19
|
20
|
18
|
16
|
16
|
14
|
13
|
12
|
11
|
9
|
8
|
6
|
5
|
5
|
3
|
22
|
21
|
19
|
|
| Accumulated Depreciation |
6
|
11
|
15
|
19
|
21
|
22
|
25
|
27
|
29
|
30
|
31
|
33
|
34
|
35
|
36
|
37
|
39
|
39
|
24
|
15
|
10
|
11
|
11
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
3
|
3
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
50
|
50
|
0
|
30
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
4
|
4
|
3
|
3
|
3
|
6
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
0
|
0
|
1
|
0
|
0
|
22
|
0
|
18
|
|
| Total Assets |
151
N/A
|
107
-29%
|
231
+116%
|
256
+11%
|
203
-21%
|
461
+127%
|
328
-29%
|
207
-37%
|
317
+53%
|
237
-25%
|
375
+58%
|
300
-20%
|
257
-14%
|
399
+55%
|
328
-18%
|
351
+7%
|
282
-20%
|
221
-21%
|
230
+4%
|
247
+8%
|
221
-11%
|
173
-22%
|
258
+49%
|
|
| Liabilities | ||||||||||||||||||||||||
| Accounts Payable |
5
|
1
|
2
|
1
|
2
|
3
|
2
|
2
|
1
|
1
|
2
|
2
|
2
|
1
|
2
|
4
|
6
|
7
|
13
|
11
|
0
|
6
|
11
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
20
|
12
|
14
|
13
|
15
|
15
|
20
|
27
|
29
|
29
|
33
|
28
|
18
|
29
|
|
| Short-Term Debt |
0
|
1
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
124
|
37
|
15
|
0
|
|
| Other Current Liabilities |
10
|
5
|
9
|
18
|
25
|
33
|
42
|
33
|
40
|
13
|
45
|
45
|
47
|
53
|
56
|
56
|
34
|
39
|
8
|
7
|
9
|
9
|
5
|
|
| Total Current Liabilities |
15
|
6
|
21
|
19
|
27
|
36
|
43
|
35
|
58
|
34
|
59
|
60
|
62
|
69
|
73
|
79
|
67
|
75
|
50
|
174
|
75
|
48
|
46
|
|
| Long-Term Debt |
11
|
10
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
195
|
195
|
196
|
197
|
198
|
240
|
95
|
131
|
95
|
96
|
|
| Other Liabilities |
0
|
0
|
0
|
69
|
63
|
90
|
85
|
74
|
49
|
50
|
211
|
169
|
138
|
120
|
94
|
117
|
85
|
41
|
42
|
37
|
35
|
40
|
35
|
|
| Total Liabilities |
25
N/A
|
17
-33%
|
21
+27%
|
88
+314%
|
91
+4%
|
126
+39%
|
128
+2%
|
109
-15%
|
106
-2%
|
84
-21%
|
270
+222%
|
229
-15%
|
199
-13%
|
384
+92%
|
363
-6%
|
393
+8%
|
348
-11%
|
314
-10%
|
332
+6%
|
306
-8%
|
242
-21%
|
183
-24%
|
177
-4%
|
|
| Equity | ||||||||||||||||||||||||
| Common Stock |
50
|
5
|
7
|
7
|
8
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
11
|
11
|
12
|
12
|
12
|
12
|
12
|
13
|
13
|
13
|
13
|
|
| Retained Earnings |
75
|
85
|
202
|
160
|
105
|
326
|
190
|
88
|
201
|
144
|
112
|
73
|
61
|
22
|
21
|
33
|
55
|
74
|
34
|
1 023
|
1 011
|
1 001
|
923
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1 030
|
1 037
|
1 042
|
1 048
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
7
|
6
|
53
|
57
|
56
|
54
|
52
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
12
|
14
|
18
|
25
|
19
|
16
|
25
|
27
|
22
|
4
|
10
|
5
|
|
| Total Equity |
125
N/A
|
90
-28%
|
210
+132%
|
168
-20%
|
112
-33%
|
335
+198%
|
200
-40%
|
98
-51%
|
210
+115%
|
153
-27%
|
106
-31%
|
71
-33%
|
58
-18%
|
15
-74%
|
35
N/A
|
41
-18%
|
67
-61%
|
93
-39%
|
102
-10%
|
59
+43%
|
21
+65%
|
10
+52%
|
81
N/A
|
|
| Total Liabilities & Equity |
151
N/A
|
107
-29%
|
231
+116%
|
256
+11%
|
203
-21%
|
461
+127%
|
328
-29%
|
207
-37%
|
317
+53%
|
237
-25%
|
375
+58%
|
300
-20%
|
257
-14%
|
399
+55%
|
328
-18%
|
351
+7%
|
282
-20%
|
221
-21%
|
230
+4%
|
247
+8%
|
221
-11%
|
173
-22%
|
258
+49%
|
|
| Shares Outstanding | ||||||||||||||||||||||||
| Common Shares Outstanding |
5
|
5
|
7
|
7
|
8
|
10
|
10
|
10
|
10
|
10
|
10
|
10
|
11
|
11
|
11
|
11
|
11
|
11
|
11
|
12
|
12
|
12
|
12
|
|
Switch to:
Switch to:
See Also
Discover More
